Theravance Biopharma Faces Major Setback as CYPRESS Trial Fails, Causing Shareholder Losses Theravance Biopharma's pivotal CYPRESS trial failed to meet primary endpoints, leading to a 26% drop in shares, prompting investor concerns.

Theravance Biopharma Faces Major Setback as CYPRESS Trial Fails, Causing Shareholder Losses #USA #New_York #Theravance_Biopharma #CYPRESS_trial #Rick_Winningham